FIELD NOTE / FULL NAME
CJC-1295
This page helps you read a CJC-1295 name accurately. The first distinction is with or without DAC, an added chemical part that binds to a protein in the blood. Those are different active ingredients. Their research and safety questions cannot be treated as if they describe one interchangeable product.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes now. A licensed U.S. provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order and are not FDA-approved.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.
Start with the signal.
CJC-1295 is a lab-made peptide, a short chain of protein building blocks. It is based on growth-hormone-releasing hormone, the natural signal from the brain to the pituitary gland. The pituitary is a small gland beneath the brain that releases growth hormone.
A growth-hormone secretagogue is a substance that prompts that release. This describes the hormone pathway. It does not establish an approved use or a result for training, recovery or aging.
Three letters change the ingredient.
With DAC
DAC means drug affinity complex. This added chemical part attaches to albumin, a common blood protein. It changes how long the substance stays in the body.
Without DAC
This form does not have that added part. FDA, the U.S. drug regulator, regards it as a different active ingredient. The FDA review found no human study of this form.
A shortened product name cannot answer which form is present. FDA has flagged inconsistent names as a safety concern because the supplied ingredient may differ from the one intended.
What was actually studied?
The published human research was small and involved healthy adults. It examined hormone levels and how the substance moves through the body. The studies appear to have used the form with DAC.
They did not measure sleep, muscle, body fat or aging. A change in a blood hormone is a different kind of finding from a result someone can expect in daily life. Long-term human safety remains uncertain.
Withdrawal is not a green light.
CJC-1295 is not FDA-approved. FDA's safety page, current as of April 22, 2026, places it among nominated ingredients whose requests were withdrawn. That is not a move into an approved group. The safety concerns remain beside the entry, and FDA does not give a withdrawal date for each substance.
Compounding means making a medicine to order. The FDA review finds that CJC-1295 does not meet the current raw-ingredient requirements for routine pharmacy compounding. A provider's prescription cannot remove those requirements. Promise lists these options for provider review. A licensed U.S. provider decides whether to prescribe. The listing does not change FDA status or the rules for the exact ingredient.
Read a label with better questions.
Is the full ingredient name supplied?
The DAC detail and the chemical form belong in the name. The general term CJC-1295 is not enough.
Does the evidence match that form?
Small studies of the DAC form do not establish evidence for the form without it.
Where does ipamorelin fit?
It is a separate peptide. The pairing guide explains why combining names does not close the research gaps.
What FDA's safety concerns include.
FDA reports serious reactions linked to CJC-1295, including a faster heart rate and flushing. It also notes dizziness and low blood pressure. FDA warns that the immune system may react to the peptide.
Source notes
Put the next step in licensed hands.
A Promise visit starts a request for review. A licensed U.S. provider decides whether to prescribe. Not everyone qualifies, and no particular treatment is promised.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes these peptides now through licensed U.S. providers. A provider reviews every request and decides. Not everyone qualifies.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.